225Ac-SSO110
Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name 225Ac-SSO110
Trade Name
Synonyms 225AcSSO110|[225Ac]Ac-SSO110
Drug Descriptions

225Ac-SSO110 is a radioconjugate comprising the alpha-radiation emitting radionuclide actinium-225 linked to the somatostatin receptor 2 (SSTR2) antagonist SSO110 (DOTA-JR11), which delivers radiation to SSTR2-expressing tumor cells, potentially resulting in decreased tumor growth (Journal of Nuclear Medicine June 2024, 65 (supplement 2) 242038).

DrugClasses
CAS Registry Number NA
NCIT ID NA

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
225Ac-SSO110 225Ac-SSO110 0 0
225Ac-SSO110 + Atezolizumab 225Ac-SSO110 Atezolizumab 0 1
225Ac-SSO110 + Avelumab 225Ac-SSO110 Avelumab 0 1
225Ac-SSO110 + Durvalumab 225Ac-SSO110 Durvalumab 0 1
225Ac-SSO110 + Pembrolizumab 225Ac-SSO110 Pembrolizumab 0 1
225Ac-SSO110 + Retifanlimab 225Ac-SSO110 Retifanlimab 0 1


Additional content available in Icon for CKB-BoostCKB BOOST